Abstract:Objective To understand the mechanism of the resistance of non‐small cell lung cancer (NSCLC) to epidermal growth factor receptor (EGFR) inhibitor treatment. Background NSCLC is one of the most common malignancies in the world, of which a group of patients have activating EGFR mutations. Icotinib and Gefitinib are two tyrosine kinase inhibitors (TKIs) that bind to the tyrosine kinase domain in EGFR and inhibit EGFR activity, which have been used to treat NSCLC. However, natural and acquired resistance significantly limits the efficacy of EGFR‐TKIs, and the mechanism of the resistance is not fully understood. Autophagy is a highly conserved, genetically programmed degradation pathway that removes damaged organelles and protein aggregates in response to various stimuli to maintain cellular homeostasis. Autophagy inhibits tumorigenesis but promotes tumor progression at later stages. Nuclear factor (erythroid‐derived 2)‐like 2 (Nrf2) is a transcription factor and regulates the expression of antioxidant genes. Activation of Nrf2 is a protective mechanism for normal cells under oxidative stress, and also for cancer cells from chemotherapeutic agents that facilitates cancer progression. Whether autophagy and Nrf2 activation contribute to the sensitivity of NSCLC to TKI treatment has been incompletely understood. Methods We compared the sensitivity of A549, an EGFR wild type cell line derived from lung carcinoma, and HCC827, an EGFR mutant cell line derived from lung adenocarcinoma, to TKI treatment, and determined the role of autophagy and Nrf2 activation in TKI‐mediated cell death. Results Icotinib and Gefitinib induced significant apoptosis in HCC827 cells in a dose‐dependent manner, while they did not cause apoptosis in A549 cells. TKI inhibitors induced autophagy flux and mTOR inhibition in HCC827 but not in A549 cells. Intriguingly, suppression of autophagy by chloroquine, a lysosomal inhibitor, did not affect TKI‐induced cell death. A549 cells had lower basal level of autophagy but higher basal level of Nrf2 activation than HCC827 cells. Brusatol, a Nrf2 inhibitor, did not affect autophagy in A549 or HCC827 cells, but significantly decreased the cell viability in A549 and HCC827 cells. However, Brusatol did not further sensitize A549 or HCC827 cells to TKI‐induced cell death. Conclusion A549 cells are more resistant to TKI‐induced apoptosis than HCC827 due to persistent activation of Nrf2. Although autophagy activity is higher in HCC827 cells than A549 cells, it is not essential for the sensitivity of HCC827 or A549 cells for TKI. Inhibition of Nrf2 reduces the cell viability of TKI resistant A549 cells although it does not show synergistic effects with TKI. Support or Funding Information NIH RO1 AA020518, NIH R01 DK 102142, P20 RR021940 (COBRE)

The Effect of Tumor Microenvironment on Autophagy and Sensitivity to Targeted Therapy in EGFR-Mutated Lung Adenocarcinoma

Advances of Autophagy and EGFR-TKI Drug Resistance in the Treatment of Non-Small Cell Lung Cancer

Knockdown of Autophagy-Related Gene LC3 Enhances the Sensitivity of HepG2 Cells to Epirubicin

EGFR Tyrosine Kinase Inhibitors Activate Autophagy As a Cytoprotective Response in Human Lung Cancer Cells

Resistance to Tyrosine Kinase-Targeted Therapy in Lung Cancer: Autophagy and Metabolic Changes

Cotargeting EGFR and autophagy signaling: A novel therapeutic strategy for non-small-cell lung cancer.

Blocking Autophagy Improves the Anti-Tumor Activity of Afatinib in Lung Adenocarcinoma with Activating EGFR Mutations in Vitro and in Vivo

Understanding the dynamics of TKI-induced changes in the tumor immune microenvironment for improved therapeutic effect

Immune effect and prognosis of transcatheter arterial chemoembolization and tyrosine kinase inhibitors therapy in patients with hepatocellular carcinoma

Changes of tumor microenvironment in non-small cell lung cancer after TKI treatments

EGFR-Mutated Non-Small Cell Lung Cancer and Resistance to Immunotherapy: Role of the Tumor Microenvironment

Exploration of the Tumor-Suppressive Immune Microenvironment by Integrated Analysis in EGFR-Mutant Lung Adenocarcinoma

EGFR-Tyrosine Kinase Inhibitors Induced Activation of the Autocrine CXCL10/CXCR3 Pathway through Crosstalk between the Tumor and the Microenvironment in EGFR-Mutant Lung Cancer

Nrf2 but Not Autophagy Activation is Associated with Resistance to Egfr Inhibitor-Induced Lung Tumor Cell Apoptosis

GATA6-upregulating Autophagy Promotes TKI Resistance in Nonsmall Cell Lung Cancer

Tumor-associated macrophages mediate resistance of EGFR-TKIs in non-small cell lung cancer: mechanisms and prospects

Targeting Tumour Microenvironment by Tyrosine Kinase Inhibitor

PD-L1 induces autophagy and primary resistance to EGFR-TKIs in EGFR-mutant lung adenocarcinoma via the MAPK signaling pathway

Overcoming EGFR-TKI resistance by targeting the tumor microenvironment

Modulation of the Tumour Microenvironment in Hepatocellular Carcinoma by Tyrosine Kinase Inhibitors: from Modulation to Combination Therapy Targeting the Microenvironment